Fierce Biotech1 min read
saveAxiom Biosciences pursues Hong Kong IPO and novel stem cell platform amid funding challenges
read at Fierce Biotech ↗Positive
Axiom Biosciences is charting an unconventional financing path by targeting a public listing in Hong Kong, with a long‑term goal of listing on the Nasdaq.
The company is developing multiple drug delivery platforms, notably a stem cell therapy that does not rely on genetic modification.
Founder and CEO Remo Moomiaie‑Qajar explained these strategies and upcoming clinical milestones on Fierce Biotech's "The Top Line" podcast.
source
This writeup was produced by pharmadog from original reporting by Fierce Biotech.
Original headline: “There's more than one way to build a biotech”
read at Fierce Biotech ↗195 words · retrieved 1h ago
comments(0)
5-min edit window · permanent after that